Antibiotic Resistance in Helicobacter Pylori: Genetic Bases and Clinical Outcomes

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

PACTR

Registry ID

PACTR202208494077478

Enrollment

100

Registered

2022-08-24

Start date

2020-11-24

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Digestive System Helicobacter Pylori

Interventions

Levofloxacin

Clarithromycin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ? All adult patients who are indicated for upper endoscopy.

Exclusion criteria

Exclusion criteria: ? Age less than 18 years old. ? Previous H. pylori treatment. ? Consumption of antibiotics or bismuth salts in the previous four weeks. ? Consumption of antisecretory drugs or sucralfate in the previous two weeks. ? A history of bleeding or a coagulation disorder that contraindicates biopsy sampling.

Design outcomes

Primary

Measure	Time frame
Eradication of H pylori defined as H pylori stool antigen negative by ELISA test	—

Secondary

Measure	Time frame
Eradication rate in H pyori with genetic resistant clarithromycin	—

Countries

Egypt

Contacts

Public ContactSamir Fathy

Benha university hospital

Samerfathi2012@gmail.com00201065264003

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026